NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that it expects to present two posters at the upcoming 19th Annual Cardiometabolic Health Congress (CMHC), taking place October 17-19, 2024, in Boston, MA.

These posters highlight Tourmaline's ongoing commitment to further characterizing inflammatory cardiovascular risk, as well as potential therapeutic mechanisms of IL-6 inhibition.

Poster Presentations:

Title: Utilization of High-Sensitivity C-Reactive Protein Testing in Primary and Secondary ASCVD Prevention
Authors: Emil deGoma, MD¹; Yung Chyung, MD¹; John Walsh, MD¹; C. William Pike, MD²; Jananee Muralidharan, MD²; Vincent Marino²; J. Craig Davis²; Saurabh Gombar, MD, PhD²; Michael D. Shapiro, DO, MCR³
Affiliations:
¹Tourmaline Bio, Inc., New York, NY, USA
²Atropos Health, Inc., New York, NY, USA
³Wake Forest University School of Medicine, Winston-Salem, NC, USA

Title: Effect of IL-6 Inhibition on Lipoprotein(a) Levels: A Systematic Review and Meta-Analysis
Authors: Saeid Mirzai, DO¹; Emil deGoma, MD²; John Walsh, MD²; Raya Mahbuba, MSc³; Yung Chyung, MD²; Michael D. Shapiro, DO, MCR¹
Affiliations:
¹Wake Forest University School of Medicine, Winston-Salem, NC, USA
²Tourmaline Bio, Inc., New York, NY, USA
³Independent researcher, Toronto, ON, Canada

For more information, please visit https://www.cardiometabolichealth.org/19th-annual-cmhc/.

About Tourmaline Bio

Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006).

About Pacibekitug

Pacibekitug (also referred to as TOUR006) is a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. Pacibekitug has been previously studied in approximately 450 participants, including patients with autoimmune disorders, across six completed clinical trials. Tourmaline is developing pacibekitug in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional diseases under consideration.

For more information about Tourmaline Bio and pacibekitug, please visit https://www.tourmalinebio.com.

Media Contact
Scient PR
Sarah Mishek
This email address is being protected from spambots. You need JavaScript enabled to view it.  

Investor Contact
Meru Advisors
Lee M. Stern
This email address is being protected from spambots. You need JavaScript enabled to view it.